|Systematic (IUPAC) name|
|Licence data||US FDA:|
|Excretion||Renal (92.3%), Faecal (2.2%)|
|Molecular mass||195.688 g/mol|
|(what is this?)|
Lorcaserin (APD-356, trade name upon approval Belviq, expected trade name during development, Lorqess) is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic. On 22 December 2009 a New Drug Application (NDA) was submitted to the Food and Drug Administration (FDA) in the United States. On 16 September 2010, an FDA advisory panel voted to recommend against approval of the drug based on concerns over both safety and efficacy. In October 2010, the FDA stated that it could not approve the application for lorcaserin in its present form.
On 10 May 2012, after a new round of studies submitted by Arena, an FDA panel voted to recommend lorcaserin with certain restrictions and patient monitoring. The restrictions include patients with a BMI of over 30, or with a BMI over 27 and a comorbidity such as high blood pressure or type 2 diabetes.
On 27 June 2012, the FDA officially approved lorcaserin for use in the treatment of obesity for adults with a BMI equal to or greater than 30 or adults with a BMI of 27 or greater who "have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol."
Mechanism of action
Lorcaserin is a selective 5-HT2C receptor agonist, and in vitro testing of the drug showed reasonable selectivity for 5-HT2C over other related targets. 5-HT2C receptors are located almost exclusively in the brain, and can be found in the choroid plexus, cortex, hippocampus, cerebellum, amygdala, thalamus, and hypothalamus. The activation of 5-HT2C receptors in the hypothalamus is supposed to activate proopiomelanocortin (POMC) production and consequently promote weight loss through satiety. This hypothesis is supported by clinical trials and other studies. While it is generally thought that 5-HT2C receptors help to regulate appetite as well as mood, and endocrine secretion, the exact mechanism of appetite regulation is not yet known. Lorcaserin has shown 100x selectivity for 5-HT2C versus the closely related 5-HT2B receptor, and 17x selectivity over the 5-HT2A receptor.
Phase 2b and other early clinical trial results
Arena states that "[d]ata from Phase 2 clinical trials of lorcaserin demonstrated that patients who received the drug experienced significantly greater weight loss than patients who received placebo." At the end of 12 weeks, patient groups that were administered lorcaserin lost an average of 4.0 pounds (10 mg/day), 5.7 pounds (15 mg/day), and 7.9 pounds (20 mg/day). The placebo group lost an average of 0.7 pounds, even though the groups received no diet or exercise instruction.
Upon discontinuation of lorcaserin treatment, lost weight is regained. In Phase 2 clinical trials, patients were tracked for 2 weeks after trial completion, and all groups regained weight more rapidly than they had lost. In preclinical trial studies, the weight of rats returned to control levels.
Phase 3 clinical trials
The lorcaserin Phase 3 program consists of three different Phase 3 trials, BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), BLOSSOM (Behavioral modification and LOrcaserin Second Study for Obesity Management), and BLOOM-DM (Diabetes Management).
BLOOM top line results were released on 30 March 2009. Measurements of efficacy using an intention to treat – last observation carried forward (ITT-LOCF) analysis showed that 47.5% of lorcaserin patients lost at least 5% of their body weight, compared to 20.3% for placebo. This result satisfies one of two alternate efficacy benchmarks in the most recent FDA draft guidance, which provides that a weight-management product can be considered effective if after one year of treatment the proportion of subjects who lose greater than or equal to 5% of baseline body weight in the active-product group is at least 35%, is approximately double the proportion in the placebo-treated group, and the difference between groups is statistically significant.
Additionally, 22.6% of lorcaserin patients lost at least 10% of their body weight, compared to 7.7% for placebo. Lorcaserin patients achieved an average weight loss of 5.8% of their body weight, or 12.7 pounds, compared to 2.2%, or 4.7 pounds, for placebo. Among the most frequent adverse events reported with lorcaserin were headache, dizziness, and nausea.
BLOSSOM results were released on 18 September 2009. Measurements of efficacy using a modified ITT-LOCF analysis showed that 47.2% of lorcaserin patients lost at least 5% of their body weight, compared to 25.0% for placebo. Lorcaserin patients achieved an average weight loss of 5.9%, or 12.7 pounds (5.7 kg), compared to 2.8%, or 6.3 pounds (2.86 kg), for placebo.
Lorcaserin had a Prescription Drug User Fee Act (PDUFA) date of 22 October 2010. On 16 September 2010, a federal advisory committee voted against recommending approval for lorcaserin. In their 9-5 vote, the committee raised concerns about the safety of the drug, particularly the findings of tumors in rats.
On 23 October 2010, the FDA decided not to approve the drug based on the available data. This was not only because cancer promoting properties could not be ruled out, but also because the weight loss efficacy was considered "marginal."
After additional studies were completed and additional information submitted to the FDA, an advisory panel was convened on 10 May 2012. The advisory panel voted 19-4-1 to recommend lorcaserin to the FDA. The FDA stated that the weight loss data passed FDA standards for efficacy and that the drug did not have cancer risks based on clarifications in the data. The FDA panelist recommended that postmarketing studies regarding potential heart valve issues be completed. The FDA has not stated one way or the other whether they believe this is necessary at this time although no related safety markers have been indicated during clinical studies. On 27 June 2012, the FDA officially approved lorcaserin for use in the treatment of obesity for some adults.
In clinical trials, the most common side effect was headache, experienced by about 18% of drug arm participants compared to 11% of placebo participants. Headache was the only reported side effect to occur at a frequency greater than 5 percentage points above those from placebo. Other reported side effects and their rates for lorcaserin and placebo patients, respectively, were as follows: upper respiratory tract infection (14.8% vs. 11.9%), nasopharyngitis (13.4% vs. 12.0%), sinusitis (7.2% vs. 8.2%), and nausea (7.5% vs. 5.4%). Adverse events of depression, anxiety, and suicidal ideation were infrequent and were reported at a similar rate in each treatment group.
On 15 September 2010 it was reported by national news media that lorcaserin was associated with the development of cancer in laboratory rats.
In December 2012, the US Drug Enforcement Administration proposed classifying lorcaserin as a Schedule IV drug because it has hallucinogenic properties at higher than approved doses and users could develop psychiatric dependencies on the drug.
There has been concern that lorcaserin can cause cardiac valvulopathy based upon the reports of subjects taking the drug in Phase 2 trials. However, a Phase 3 clinical trial of the drug was conducted and the results published in the October 2014 Postgraduate Medicine journal, a peer-reviewed medical journal for physicians. These results found no statistically significant differences in valvulopathy rates compared to control, being 2.3% for the drug subjects and 2.2% for controls.
- "BELVIQ (lorcaserin hydrochloride) tablet [Eisai, Inc]". DailyMed. Eisai, Inc. August 2012. Retrieved 21 October 2013.
- "FDA approves Arena obesity drug; first in 13 years". Reuters. 27 June 2012.
- "Belviq". Trademarkia. 23 Jun 2011. Retrieved 27 June 2012.
- "Lorqess". EvaluatePharma. 7 September 2010. Retrieved 13 September 2010.
- "Lorqess". Trademarkia. 25 March 2010. Retrieved 13 September 2010.
- "Lorcaserin New Drug Application". Drugs.com. 22 December 2009.
- Andrew Pollack (16 September 2010). "F.D.A. Panel Urges Denial of Diet Drug". New York Times.
- "FDA Issues Complete Response Letter for Lorcaserin New Drug Application". 23 October 2010.
- "New Diet Drug Lorcaserin Wins Vote From FDA Panel". webmd. 10 May 2012.
- "FDA approves lorcaserin, first weight-loss drug OK'd since 1999". Los Angeles Times. June 27, 2012.
- "DEPARTMENT OF JUSTICE Drug Enforcement Administration 21 CFR Part 1308, Placement of Lorcaserin into Schedule IV".
- Wilson, Megan R. (December 19, 2012). "Reg Watch". The Hill.
- Thomsen, W. J.; Grottick, A. J.; Menzaghi, F.; Reyes-Saldana, H.; Espitia, S.; Yuskin, D.; Whelan, K.; Martin, M.; Morgan, M.; Chen, W.; Al-Shamma, H.; Smith, B.; Chalmers, D.; Behan, D. (2008). "Lorcaserin, a Novel Selective Human 5-Hydroxytryptamine2C Agonist: in Vitro and in Vivo Pharmacological Characterization". Journal of Pharmacology and Experimental Therapeutics 325 (2): 577–587. doi:10.1124/jpet.107.133348. PMID 18252809.
- US patent 6953787, Brian Smith, Jeffrey Smith, "5HT2c receptor modulators", published 2003-10-04, issued 2005-11-10
- US patent 7704993, Brian Smith, Charles A. Gilson, III, Jeffrey Schultz, Jeffrey Smith, "Benzazepine derivatives and methods of prophylaxis or treatment of 5ht2c receptor associated diseases", published 2004-16-06, issued 2010-27-04
- US patent 8207158, Brian Smith, Jeffrey Smith, "5HT2c receptor modulators", published 2011-27-05, issued 2012-26-06
- Spreitzer, Helmut (13 September 2010). "Lorcaserin". Österreichische Apothekerzeitung (in German) 64 (19): 1083.
- Millan, M. J. (2005). "Serotonin 5-HT2C receptors as a target for the treatment of depressive and anxious states: focus on novel therapeutic strategies". Therapie 60 (5): 441–460. doi:10.2515/therapie:2005065. PMID 16433010.
- Smith, B. M.; Smith, J. M.; Tsai, J. H.; Schultz, J. A.; Gilson, C. A.; Estrada, S. A.; Chen, R. R.; Park, D. M.; Prieto, E. B.; Gallardo, C. S.; Sengupta, D.; Thomsen, W. J.; Saldana, H. R.; Whelan, K. T.; Menzaghi, F.; Webb, R. R.; Beeley, N. R. A. (2005). "Discovery and SAR of new benzazepines as potent and selective 5-HT2C receptor agonists for the treatment of obesity". Bioorganic & Medicinal Chemistry Letters 15 (5): 1467–1470. doi:10.1016/j.bmcl.2004.12.080. PMID 15713408.
- Smith, B. M.; Smith, J. M.; Tsai, J. H.; Schultz, J. A.; Gilson, C. A.; Estrada, S. A.; Chen, R. R.; Park, D. M.; Prieto, E. B.; Gallardo, C. S.; Sengupta, D.; Dosa, P. I.; Covel, J. A.; Ren, A.; Webb, R. R.; Beeley, N. R. A.; Martin, M.; Morgan, M.; Espitia, S.; Saldana, H. R.; Bjenning, C.; Whelan, K. T.; Grottick, A. J.; Menzaghi, F.; Thomsen, W. J. (2008). "Discovery and Structure−Activity Relationship of (1R)-8-Chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a Selective Serotonin 5-HT2CReceptor Agonist for the Treatment of Obesity". Journal of Medicinal Chemistry 51 (2): 305–313. doi:10.1021/jm0709034. PMID 18095642.
- "Lorcaserin Hydrochloride for Obesity".[dead link]
- "Arena Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results of Novel Anti-Obesity Compound". Arena Pharmaceuticals. 13 December 2009.
- http://www.arenapharm.com/wt/page/bloom.html[dead link]
- Smith, Steven R.; Neil J. Weissman, M.D., Christen M. Anderson, M.D., Ph.D., Matilde Sanchez, Ph.D., Emil Chuang, M.D., Scott Stubbe, M.B.A., Harold Bays, M.D., William R. Shanahan, M.D. (July 15, 2010). "Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management". N Engl J Med (363): 245–256. doi:10.1056/NEJMoa0909809. PMID 20647200. Retrieved 4 April 2011.
- http://www.arenapharm.com/wt/page/blossom.html[dead link]
- O'Neil, P. M.; Smith, S. R.; Weissman, N. J.; Fidler, M. C.; Sanchez, M.; Zhang, J.; Raether, B.; Anderson, C. M.; Shanahan, W. R. (2012). "Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study". Obesity 20 (7): 1426–1436. doi:10.1038/oby.2012.66. PMID 22421927.
- Arena Pharmaceuticals Announces Notification of Tentative September 16th FDA Advisory Committee Meeting to Review Lorcaserin for Weight Management, 2 June 2010
- Pollack, Andrew (16 September 2010). "F.D.A. Panel Rejects Diet Pill". The New York Times.
- Larkin, Catherine (15 September 2010). "FDA staff says Arena diet pill linked to cancer". SFGate.
- "Schedules of Controlled Substances: Placement of Lorcaserin into Schedule IV".